News
Epygenix Therapeutics Announces Appointment of G. Michael Landis as Chief Financial Officer
Epygenix Therapeutics Announces Appointment of Darren Cline as CEO
Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome
Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome
Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome
Read Full Press Release: https://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-200-in-lennox-gastaut-syndrome-301345811.html
Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies
Read Full Press Release Here: https://www.fiercepharma.com/sponsored/journey-from-aquarium-to-bedside-to-treat-genetic-epilepsies
Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
Read Full Press Release Here: https://www.prnewswire.com/news-releases/epygenix-therapeutics-initiates-phase-2-study-for-dravet-syndrome-with-epx-100-301133241.html
EpyGenix Launches Phase II Trial for EPX-100
Read Full News Article Here: https://www.dravetfoundation.org/2020-epygenix-launches-phaseii-trial-for-epx-100-9-04-20/
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Read Full Press Release Here: https://www.prnewswire.com/news-releases/epygenix-therapeutics-successfully-completes-epx-100-phase-i-placebo-controlled-double-blind-2-period-study-and-ready-to-phase-2-studies-300993228.html
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Read Full Press Release Here: https://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-ind-approval-of-epx-100-for-the-treatment-of-dravet-syndrome-300892063.html
Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
Read Full Release Here: https://www.prnewswire.com/news-releases/epygenix-therapeutics-submits-investigational-new-drug-application-for-epx-100-to-the-us-fda-for-the-treatment-of-patients-with-dravet-syndrome-300872863.html
A New School of Drug Discovery
https://www.epygenix.com/wp-content/uploads/2021/05/laban.1296.pdf
Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome
https://www.newswire.com/news/epygenix-therapeutics-receives-orphan-drug-designation-from-the-u-s-19369643...
Epilepsy drug discovered in fish model shows promise in small pediatric clinical trial
https://www.nih.gov/news-events/news-releases/epilepsy-drug-discovered-fish-model-shows-promise-small-pediatric-clinical-trial
Through the Looking Glass: The Quest by Parents and Scientists to End Pediatric Epilepsy
https://www.ucsf.edu/news/2017/01/405491/through-looking-glass-quest-parents-and-scientists-end-pediatric-epilepsy
Potential Drug Discovered for Severe Form of Epilepsy
https://www.ucsf.edu/news/2013/08/108521/potential-epilepsy-drug-discovered-using-zebrafish